![A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017 A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017](https://journals.sagepub.com/cms/10.1177/1073110517750609/asset/images/large/10.1177_1073110517750609-fig1.jpeg)
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel ( CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
![Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents | Fierce Pharma Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1597239104/GettyImages-1141713510.jpg/GettyImages-1141713510.jpg?VersionId=2TulzrgHkUcCbELeWNrWk.khPeq6IxoC)
Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents | Fierce Pharma
![Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-17175-8/MediaObjects/41467_2020_17175_Fig1_HTML.png)
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
![Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-019-13880-1/MediaObjects/41467_2019_13880_Fig1_HTML.png)
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
![Frontiers | Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities Frontiers | Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities](https://www.frontiersin.org/files/Articles/555516/fonc-10-01227-HTML/image_m/fonc-10-01227-g001.jpg)
Frontiers | Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
![The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41419-018-0918-x/MediaObjects/41419_2018_918_Fig1_HTML.png)
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
![Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada | Fierce Pharma Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1580400509/shutterstock_79462060.jpg/shutterstock_79462060.jpg?VersionId=rgc4NVQ7qAlbJ5CTyhBb8RsNWIfP4sJ6)
Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada | Fierce Pharma
![Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development](https://www.cell.com/cms/attachment/14a0c96c-7152-4f32-af9c-af539bbf4ad1/gr5.jpg)
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
![Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results | Nature Medicine Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-02182-7/MediaObjects/41591_2022_2182_Fig1_HTML.png)
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results | Nature Medicine
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
![Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-020-1061-7/MediaObjects/41591_2020_1061_Fig1_HTML.png)
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
![Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41571-018-0075-2/MediaObjects/41571_2018_75_Fig1_HTML.png)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
![Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development](https://www.cell.com/cms/attachment/d00e1e5d-800c-4aa3-9bbf-922f336645fb/gr4.jpg)